Protective effect of Korean red ginseng on oxaliplatin-mediated splenomegaly in colon cancer

Jeonghyun Kang, Joon Seong Park, Sung Gwe Ahn, Jin Hong Lim, Seung Hyuk Baik, Dong Sup Yoon, Kang Young Lee, Joon Jeong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: This study investigated how adding Korean red ginseng extract (KRG) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy affected the rate of splenomegaly in colon cancer. Methods: This retrospective study analyzed 42 patients who were randomly assigned to receive a FOLFOX regimen with or without KRG. Spleen volume change was assessed by computed tomography scans measured before surgery (presurgery volume) and 3 weeks after cessation of the 12th cycle of FOLFOX (postchemotherapy volume). Results: All patients showed increased spleen volume. No difference was observed in median presurgery and postchemotherapy volume between the KRG and control groups. However, a ratio defined as postchemotherapy volume divided by presurgery volume was significantly lower in the KRG group than the control group (median, 1.38 [range, 1.0–2.8] in KRG group vs. median, 1.89 [range, 1.1–3.0] in control group, P = 0.028). When splenomegaly was defined as a >61% increase in spleen volume, the rate of splenomegaly was significantly lower in the KRG group than the control group (28.6% vs. 61.9%, P = 0.03). KRG consumption was inversely associated with developing splenomegaly in multivariate analysis. Conclusion: Adding KRG during FOLFOX chemotherapy for colon cancer might protect against oxaliplatin-induced splenomegaly. The protective effect of Korean red ginseng should be investigated with further research.

Original languageEnglish
Pages (from-to)161-167
Number of pages7
JournalAnnals of Surgical Treatment and Research
Volume95
Issue number3
DOIs
Publication statusPublished - 2018 Sep

Fingerprint

oxaliplatin
Panax
Splenomegaly
Colonic Neoplasms
Leucovorin
Fluorouracil
Control Groups
Spleen
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Kang, Jeonghyun ; Park, Joon Seong ; Ahn, Sung Gwe ; Lim, Jin Hong ; Baik, Seung Hyuk ; Yoon, Dong Sup ; Lee, Kang Young ; Jeong, Joon. / Protective effect of Korean red ginseng on oxaliplatin-mediated splenomegaly in colon cancer. In: Annals of Surgical Treatment and Research. 2018 ; Vol. 95, No. 3. pp. 161-167.
@article{2329fa99fca24952a46245c22a7a283a,
title = "Protective effect of Korean red ginseng on oxaliplatin-mediated splenomegaly in colon cancer",
abstract = "Purpose: This study investigated how adding Korean red ginseng extract (KRG) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy affected the rate of splenomegaly in colon cancer. Methods: This retrospective study analyzed 42 patients who were randomly assigned to receive a FOLFOX regimen with or without KRG. Spleen volume change was assessed by computed tomography scans measured before surgery (presurgery volume) and 3 weeks after cessation of the 12th cycle of FOLFOX (postchemotherapy volume). Results: All patients showed increased spleen volume. No difference was observed in median presurgery and postchemotherapy volume between the KRG and control groups. However, a ratio defined as postchemotherapy volume divided by presurgery volume was significantly lower in the KRG group than the control group (median, 1.38 [range, 1.0–2.8] in KRG group vs. median, 1.89 [range, 1.1–3.0] in control group, P = 0.028). When splenomegaly was defined as a >61{\%} increase in spleen volume, the rate of splenomegaly was significantly lower in the KRG group than the control group (28.6{\%} vs. 61.9{\%}, P = 0.03). KRG consumption was inversely associated with developing splenomegaly in multivariate analysis. Conclusion: Adding KRG during FOLFOX chemotherapy for colon cancer might protect against oxaliplatin-induced splenomegaly. The protective effect of Korean red ginseng should be investigated with further research.",
author = "Jeonghyun Kang and Park, {Joon Seong} and Ahn, {Sung Gwe} and Lim, {Jin Hong} and Baik, {Seung Hyuk} and Yoon, {Dong Sup} and Lee, {Kang Young} and Joon Jeong",
year = "2018",
month = "9",
doi = "10.4174/astr.2018.95.3.161",
language = "English",
volume = "95",
pages = "161--167",
journal = "Annals of Surgical Treatment and Research",
issn = "2288-6575",
publisher = "Korean Surgical Society",
number = "3",

}

Protective effect of Korean red ginseng on oxaliplatin-mediated splenomegaly in colon cancer. / Kang, Jeonghyun; Park, Joon Seong; Ahn, Sung Gwe; Lim, Jin Hong; Baik, Seung Hyuk; Yoon, Dong Sup; Lee, Kang Young; Jeong, Joon.

In: Annals of Surgical Treatment and Research, Vol. 95, No. 3, 09.2018, p. 161-167.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Protective effect of Korean red ginseng on oxaliplatin-mediated splenomegaly in colon cancer

AU - Kang, Jeonghyun

AU - Park, Joon Seong

AU - Ahn, Sung Gwe

AU - Lim, Jin Hong

AU - Baik, Seung Hyuk

AU - Yoon, Dong Sup

AU - Lee, Kang Young

AU - Jeong, Joon

PY - 2018/9

Y1 - 2018/9

N2 - Purpose: This study investigated how adding Korean red ginseng extract (KRG) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy affected the rate of splenomegaly in colon cancer. Methods: This retrospective study analyzed 42 patients who were randomly assigned to receive a FOLFOX regimen with or without KRG. Spleen volume change was assessed by computed tomography scans measured before surgery (presurgery volume) and 3 weeks after cessation of the 12th cycle of FOLFOX (postchemotherapy volume). Results: All patients showed increased spleen volume. No difference was observed in median presurgery and postchemotherapy volume between the KRG and control groups. However, a ratio defined as postchemotherapy volume divided by presurgery volume was significantly lower in the KRG group than the control group (median, 1.38 [range, 1.0–2.8] in KRG group vs. median, 1.89 [range, 1.1–3.0] in control group, P = 0.028). When splenomegaly was defined as a >61% increase in spleen volume, the rate of splenomegaly was significantly lower in the KRG group than the control group (28.6% vs. 61.9%, P = 0.03). KRG consumption was inversely associated with developing splenomegaly in multivariate analysis. Conclusion: Adding KRG during FOLFOX chemotherapy for colon cancer might protect against oxaliplatin-induced splenomegaly. The protective effect of Korean red ginseng should be investigated with further research.

AB - Purpose: This study investigated how adding Korean red ginseng extract (KRG) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy affected the rate of splenomegaly in colon cancer. Methods: This retrospective study analyzed 42 patients who were randomly assigned to receive a FOLFOX regimen with or without KRG. Spleen volume change was assessed by computed tomography scans measured before surgery (presurgery volume) and 3 weeks after cessation of the 12th cycle of FOLFOX (postchemotherapy volume). Results: All patients showed increased spleen volume. No difference was observed in median presurgery and postchemotherapy volume between the KRG and control groups. However, a ratio defined as postchemotherapy volume divided by presurgery volume was significantly lower in the KRG group than the control group (median, 1.38 [range, 1.0–2.8] in KRG group vs. median, 1.89 [range, 1.1–3.0] in control group, P = 0.028). When splenomegaly was defined as a >61% increase in spleen volume, the rate of splenomegaly was significantly lower in the KRG group than the control group (28.6% vs. 61.9%, P = 0.03). KRG consumption was inversely associated with developing splenomegaly in multivariate analysis. Conclusion: Adding KRG during FOLFOX chemotherapy for colon cancer might protect against oxaliplatin-induced splenomegaly. The protective effect of Korean red ginseng should be investigated with further research.

UR - http://www.scopus.com/inward/record.url?scp=85053796407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053796407&partnerID=8YFLogxK

U2 - 10.4174/astr.2018.95.3.161

DO - 10.4174/astr.2018.95.3.161

M3 - Article

AN - SCOPUS:85053796407

VL - 95

SP - 161

EP - 167

JO - Annals of Surgical Treatment and Research

JF - Annals of Surgical Treatment and Research

SN - 2288-6575

IS - 3

ER -